These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 16415900

  • 1. Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen.
    Frère P, Baron F, Bonnet C, Hafraoui K, Pereira M, Willems E, Fillet G, Beguin Y.
    Bone Marrow Transplant; 2006 Feb; 37(4):411-8. PubMed ID: 16415900
    [Abstract] [Full Text] [Related]

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 3. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation.
    Nachbaur D, Larcher C, Kircher B, Eibl G, Nussbaumer W, Gunsilius E, Haun M, Grünewald K, Gastl G.
    Ann Hematol; 2003 Oct; 82(10):621-7. PubMed ID: 12920570
    [Abstract] [Full Text] [Related]

  • 4. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [Abstract] [Full Text] [Related]

  • 5. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.
    Piñana JL, Martino R, Barba P, Margall N, Roig MC, Valcárcel D, Sierra J, Rabella N.
    Bone Marrow Transplant; 2010 Mar; 45(3):534-42. PubMed ID: 19668235
    [Abstract] [Full Text] [Related]

  • 6. Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection.
    Kim DH, Kim JG, Lee NY, Sung WJ, Sohn SK, Suh JS, Lee KS, Lee KB.
    Bone Marrow Transplant; 2004 Jul; 34(1):21-7. PubMed ID: 15133483
    [Abstract] [Full Text] [Related]

  • 7. Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen.
    Mohty M, Mohty AM, Blaise D, Faucher C, Bilger K, Isnardon D, Sainty D, Gastaut JA, Viens P, Olive D, Gaugler B.
    Bone Marrow Transplant; 2004 Apr; 33(8):839-46. PubMed ID: 14767500
    [Abstract] [Full Text] [Related]

  • 8. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS.
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [Abstract] [Full Text] [Related]

  • 9. Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation.
    Mossad SB, Avery RK, Longworth DL, Kuczkowski EM, McBee M, Pohlman BL, Sobecks RM, Kalaycio ME, Andresen SW, Macklis RM, Bolwell BJ.
    Bone Marrow Transplant; 2001 Sep; 28(5):491-5. PubMed ID: 11593323
    [Abstract] [Full Text] [Related]

  • 10. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M, Barker JN, Miller JS, Arora M, Wagner JE, Burns LJ, MacMillan ML, Douek D, DeFor T, Tan Y, Repka T, Blazar BR, Weisdorf DJ.
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [Abstract] [Full Text] [Related]

  • 11. HLA-DRB1*09 is associated with increased incidence of cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation.
    Du J, Liu J, Gu J, Zhu P.
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1417-21. PubMed ID: 18022570
    [Abstract] [Full Text] [Related]

  • 12. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C, Meijer E, Petersen EJ, Lokhorst HM, Verdonck LF.
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [Abstract] [Full Text] [Related]

  • 13. Incidence of human cytomegalovirus infection in patients with refractory solid tumors receiving nonmyeloablative allogeneic stem cell transplants versus recipients of standard SCT for hematologic malignancies.
    Zambelli A, Lilleri D, Pedrazzoli P, Peccatori J, Baldanti F, Fregoni V, Ciceri F, Caldera D, Renga M, Colombo AA, Alessandrino EP, Gerna G, Da Prada GA, Siena S, Bregni M.
    Biol Blood Marrow Transplant; 2005 Jun; 11(6):423-8. PubMed ID: 15931630
    [Abstract] [Full Text] [Related]

  • 14. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Shigematsu A, Yasumoto A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Ota S, Sato N, Takahata M, Okada K, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
    [Abstract] [Full Text] [Related]

  • 15. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients.
    Heining C, Spyridonidis A, Bernhardt E, Schulte-Mönting J, Behringer D, Grüllich C, Jakob A, Bertz H, Finke J.
    Bone Marrow Transplant; 2007 May; 39(10):613-22. PubMed ID: 17384658
    [Abstract] [Full Text] [Related]

  • 16. Early infections in adult patients undergoing unrelated donor cord blood transplantation.
    Saavedra S, Sanz GF, Jarque I, Moscardó F, Jiménez C, Lorenzo I, Martín G, Martínez J, De La Rubia J, Andreu R, Mollá S, Llopis I, Fernández MJ, Salavert M, Acosta B, Gobernado M, Sanz MA.
    Bone Marrow Transplant; 2002 Dec; 30(12):937-43. PubMed ID: 12476288
    [Abstract] [Full Text] [Related]

  • 17. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Michallet M, Le QH, Mohty M, Prébet T, Nicolini F, Boiron JM, Esperou H, Attal M, Milpied N, Lioure B, Bordigoni P, Yakoub-Agha I, Bourhis JH, Rio B, Deconinck E, Renaud M, Chir Z, Blaise D.
    Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
    [Abstract] [Full Text] [Related]

  • 18. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P, Stelljes M, Vogel W, Hägele M, Handgretinger R, Kanz L.
    Blood Cells Mol Dis; 2008 May; 40(1):13-9. PubMed ID: 17869547
    [Abstract] [Full Text] [Related]

  • 19. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
    Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Smith C, Gong JZ, Lagoo A, Niedzwiecki D, Dowell JM, Waters-Pick B, Liu C, Marshall D, Vredenburgh JJ, Gockerman J, Decastro C, Moore J, Chao NJ.
    J Clin Oncol; 2007 Feb 20; 25(6):690-7. PubMed ID: 17228020
    [Abstract] [Full Text] [Related]

  • 20. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity.
    Bethge WA, Haegele M, Faul C, Lang P, Schumm M, Bornhauser M, Handgretinger R, Kanz L.
    Exp Hematol; 2006 Dec 20; 34(12):1746-52. PubMed ID: 17157172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.